Carregant...

CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for Bortezomib sensitivity in multiple myeloma

Bortezomib (BTZ) is highly effective in the treatment of Multiple Myeloma (MM), however emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to BTZ resistance. Specifically, we engineered an RPMI8226 MM cell li...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Shi, Chang-Xin, Kortüm, K. Martin, Zhu, Yuan Xiao, Bruins, Laura A., Jedlowski, Patrick, Votruba, Patrick G., Luo, Moulun, Stewart, Robert A., Ahmann, Jonathan, Braggio, Esteban, Stewart, A. Keith
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5796678/
https://ncbi.nlm.nih.gov/pubmed/28958990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0130
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!